A Phase III, Multicenter, Randomized, Double-Blind, Placebo-COntrolled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease Save

Date Added
November 27th, 2018
PRO Number
Pro00082763
Researcher
Nicholas Milano

List of Studies


Profiles_link
Keywords
Alzheimers, Memory Loss
Summary

This study will evaluate the efficacy and safety of gantenerumab compared with placebo in patients with early Alzheimer's Disease.

Study duration for each subject will include a 12 week screening period (including the optional prescreening period), followed by a double-blind treatment period of 102 weeks of study drug treatment plus a visit 2 weeks after the last dose (week 104), and followed by the post-double-blind treatment period of two follow-up visits at 14 and 50 weeks after the last dose (weeks 116 and 152 respectively). Thus for a patient not entering the OLE, the maximum length of study is approximately 164 weeks.

Institution
MUSC
Recruitment Contact
Aparna Choudhury
843-792-2845
Choudhur@MUSC.edu

Change_preferences

-- OR --

Create_login